Rejuvel Bio-Sciences, Inc.

Rejuvel Bio-Sciences, Inc., a development stage company, produces, distributes, markets, and sells skin care products worldwide. The company primarily offers skin cream under the Rejuvel brand. It also intends to develop, build, and sell environmental management solutions that use electron particle accelerator technology for the treatment of drinking water, municipal and industrial wastewater, sludge, and produced water from oil and gas fracturing activities. The company was formerly known as Technology Applications International Corporation and changed its name to Rejuvel Bio-Sciences, Inc. in June 2015. Rejuvel Bio-Sciences, Inc. was founded in 2009 and is headquartered in Miami, Florida.

Rejuvel Bio-Sciences, Inc. trades as NUUU on OTC. The company is classified in Consumer Defensive / Household & Personal Products and reports in USD.

The current profile places the business in Household & Personal Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $94,096 of revenue and -$352,865 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Rejuvel Bio-Sciences, Inc. can be compared against peers such as Bemax Inc., 1606 Corp., EQ Energy Drink, Inc., Gunther Grant, Inc., Greyson International, Inc., Healthy Coffee International, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $117,765, beta of -131.85, and return on equity of +42.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

NUUU currently shows total debt of $157,068 and beta of -131.85. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.rejuvel.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.